Wearable Cervical Health Platform

The gap between what your body knows and what your doctor sees is enormous

AIDLAS is a multi-physics wearable platform for continuous cervical spine monitoring, biomechanical assessment, and adaptive therapeutic intelligence. Five sensing modalities. Twenty-five patents. Built from lived experience with a C4-C6 fusion.

“I woke up from spinal surgery and realized the only person tracking my recovery was me. The device that should have existed — one that watches the cervical spine continuously, learns your movement patterns, and catches the compensation cascades before they become new injuries — didn’t. So I built it.”

— Founder & CTO, iJarvis LLC
25
Patents Filed
303+
Claims
5
Sensing Modalities
2
Hardware Generations

Five physics, one wearable

AIDLAS integrates multiple independent tissue-sensing modalities into a single cervical wearable. Each modality provides a distinct window into what’s happening at and around the spine. Together, they form a composite picture no single measurement can provide.

Inertial Kinematics

9-axis IMU tracking cervical range of motion, angular velocity, postural alignment, and compensatory movement patterns in real time. Multi-node differential angles detect asymmetric loading.

Photoacoustic Spectroscopy

Continuous-wave LED illumination with synchronous demodulation for tissue characterization. Near-infrared spectroscopy measures hemodynamic changes and tissue oxygenation at the cervical site.

Piezoelectric Sensing

PVDF polymer film transducers capture acoustic emissions, swallowing dynamics, and micro-vibrations. Multi-function: simultaneous sensing and bone conduction therapeutic feedback.

Bioelectrical Impedance

Tissue impedance measurements track fluid shifts, edema, and compositional changes in the cervical region over time. Detects inflammatory responses that precede symptomatic episodes.

Bone Conduction Biofeedback

ACAD (Attentional Capture Alert Design) framework delivers psychoacoustically optimized alerts via dual bone conduction transducers. Prediction-error scheduling ensures alerts remain salient without habituation.

25 provisionals. 303+ claims. Filed Feb–Apr 2026.

The AIDLAS patent portfolio spans the full stack from sensor hardware to therapeutic intelligence to clinical imaging. Seven umbrella non-provisional filings are in preparation for conversion by February 2027.

Sensing & Hardware

Multi-node body monitoring, PVDF transducers, photoacoustic spectroscopy, CMUT array imaging, unified multi-physics aperture, and continuous wearable tissue monitoring.

Intelligence & Algorithms

Adaptive threshold engine, biomechanical fingerprinting, compensation drift detection, movement safety intelligence, and real-time hazard modeling.

Therapeutic Systems

Multi-tissue therapeutic management, healing digital twin, post-surgical recovery tracking, osteogenic stimulation, and closed-loop bone health monitoring.

Clinical & Imaging

MRI complement / imaging referral reduction, 3D hemodynamic mapping, spectroscopic tissue typing, and multi-species acoustic respiratory monitoring.

Two generations, converging on clinical

Gen 1 — Breadboard

Validation Platform

ESP32-S3 dual-core, BNO085 IMU, optical chain (NIR LEDs, TIA, ADC), PVDF transducers, bone conduction alerting. BOM ~$540. Validates all five modalities and firmware (v3.0, 6,500+ lines). Currently in hardware assembly.

Gen 2 — CMUT Clinical

Clinical Platform

Capacitive micromachined ultrasonic transducer array for volumetric tissue imaging. Row-column addressed architecture. Intended for clinical trial deployment. Protected by AIDLAS-012 through AIDLAS-016.

Path to market

Q1 2026

IP Foundation

25 provisional patents filed. 303+ claims. Seven umbrella non-provisional filings drafted. SAM.gov registration and CAGE code in progress for federal grant eligibility.

Q2 2026

Gen 1 Hardware Build

Complete breadboard assembly. Validate all five sensing modalities against known reference data. Firmware integration testing. First wearable data collection on the inventor’s own cervical spine.

Q3-Q4 2026

Grant Applications & Fundraise

NIH SBIR Phase I ($275K) post-reauthorization. NSF SBIR. Wefunder community raise at $9M target, $18.75M pre-money valuation. Data from Gen 1 supports all applications.

2027

Non-Provisional Conversion & Clinical Pathway

Convert provisionals to seven umbrella non-provisional patents. Begin FDA pre-submission process. Gen 2 CMUT development if grant-funded. eRA Commons and Grants.gov fully active for NIH pipeline.

Get in Touch

Clinicians, researchers, investors, and potential collaborators.

Or write to hello@ijarvis.ai

Message sent.

We’ll be in touch.